Adenosine phosphate
Highest phase reached
Approved
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Adenosine phosphate
- Molecular weight
- 347.22
- Structure (SMILES)
- Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]1O
- adenyl
- Adenyl
- 5 adenylic acid
- 5 adenylic acid fcc
- 5 adenylic acid mi
- 5 adenylic acid usp rs
- 5'-adenylic acid
- 5'-ADENYLIC ACID [FCC]
- 5'-ADENYLIC ACID [MI]
- 5'-ADENYLIC ACID [USP-RS]
- a 5mp
- A 5MP
- A-5MP
- adenosine 5 dihydrogen phosphate
- adenosine 5 monophosphoric acid
- ADENOSINE 5'-(DIHYDROGEN PHOSPHATE).
- Adenosine 5'-monophosphoric acid
- Adenosine Mono Phosphate (AMP)
- adenosine mono phosphate amp
- adenosine monophosphate
- Adenosine Monophosphate
- Adenosine monophosphate (amp)
- adenosine monophosphate amp
- adenosine phosphate
- Adenosine phosphate
- ADENOSINE PHOSPHATE [HSDB]
- adenosine phosphate [INN]
And 23 more, listed on the interactive page.
- ATC classification codes
- C01EB10
Sources for recorded values
- CAS registry numbers
- 61-19-8
- ChEMBL ID
- CHEMBL752
- InChIKey
- UDMBCSSLTHHNCD-KQYNXXCUSA-N
- PubChem compound IDs
- 6083
- FDA ingredient codes (UNII)
- 415SHH325A
- 296
- 309
- Applicant
- ASTELLAS
- Approval date
- 30 Oct 1989
- Application number
- NDA019937
- First in class
- No
- Orphan designation
- No
- Availability
- Withdrawn
- Pharmacology name
- adenosine 5'-monophosphate
- Type
- Metabolite
- Drug name stem
- -nosine
- Action type
- ACTIVATION
- Target
- AMP kinase
- Gene symbol
- AMP kinase
- Action
- Activation
- Action type
- ACTIVATION
- Target
- AMP kinase
- Gene symbol
- AMP kinase
- Median affinity
- 4.21
- Affinity units
- pEC50
- Action
- Antagonist
- Action type
- Antagonist
- Target
- TRPM4
- Gene symbol
- TRPM4
- Protein identifier
- Q8TD43
- Median affinity
- 4.7
- Affinity units
- pIC50
DrugCentral mechanisms
- Action type
- GATING INHIBITOR
- Gene symbol
- TRPM4
- Protein identifier
- Q8TD43
- Organism
- Homo sapiens
- Target development level
- Chemical evidence
Investigated indications
- Condition
- Ischemia
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000556
- Subject identifier
- D007511
Open Targets indications
- Condition identifier
- EFO_0000556
- Highest recorded phase
- 1
Warnings
- Warning
- Withdrawn
- Description
- Not safe or effective for intended use as vasodilator, anti-inflammatory
- Year
- 1973
- Warning
- Withdrawn
- Description
- Not safe or effective for intended use as vasodilator, anti-inflammatory
- Year
- 1973
- Country
- United States
- Condition
- adverse effect
- Warning
- Withdrawn
- Description
- Not safe or effective for intended use as vasodilator, anti-inflammatory
- Year
- 1973
- Country
- United States
- Condition
- lack of efficacy
Reported adverse events
- Event
- drug hypersensitivity
- Reports
- 11
- Reporting signal score
- 32.2162
Trial references
- NCT00179010
- Dose
- 10 drops
- Route
- Sublingual
- How often
- 3 times a day
Conditions of use
- As directed by your healthcare professional
- Hydrogen bond acceptors
- 10
- Hydrogen bond donors
- 5
- Polar surface area
- 186.07
- Calculated partition coefficient (ALogP)
- -1.86
- Calculated partition coefficient (XLogP)
- -3.5
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 4
- Heavy atoms
- 23
- Molecular formula
- C10H14N5O7P
- Monoisotopic mass
- 347.06308480
- Natural product
- Yes
- Recorded assays
- 958
- Active assays
- 98
- Confirmatory
- Other
- Screening
- Summary
Solubility
- Median
- 432,000
- Mean
- 432,000
- Minimum
- 432,000
- Maximum
- 432,000
- Unit
- nM
- Assays
- 1
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- Solubility
Related records
Trials (84)
- A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCI
- A Single Center Diagnostic, Cross-sectional Study of Coronary Microvascular Dysfunction
- A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age
- A Trial to Compare American Heart Association (AHA) and Simple (SIM)Method to Give Adenosine to Treat Supra-ventricular Tachycardia (SVT)
- Adenosin to Rapidly Reverse Left Ventricle Impairment in Takotsubo Syndrome
- Adenosine and A2A Receptors in Human Brown Adipose Tissue
- Adenosine and Magnesium Sulphate as Adjuvants for PECS Block.
- Adenosine as an Adjunct to Blood Cardioplegia
- Adenosine Cardioplegia; Improved Cardioprotection?
- Adenosine Contrast CorrELations in Evaluating RevAscularizaTION
- Adenosine Effect on Persistent Pulmonary Vein Isolation Line Evaluation (APPLE Trial)
- Adenosine Receptors Influence Ischemia-Reperfusion Injury
- Adenosine to Assess Complete Conduction Block During Catheter Ablation of Paroxysmal Atrial Fibrillation
- Adenosine Versus Verapamil for Management of Supraventricular Tachycardia Post- Coronary Artery Bypass Grafting
- Adenosine vs Diltiazem for Treatment of SVT in the ED
- Adenosine vs. Diltiazem
- Adenosine's Effect on STunning Resolution in Acute Myocardial Infarction
- Adrenaline for the Treatment of No-Reflow in Normotensive Patients
- ADVANCE MPI 1: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)
- ADVANCE MPI 2: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)
In development for (1)
- Ischemic disease Phase 1